期刊文献+

STAT3在食管胃交界部腺癌中的表达及意义 被引量:3

Expression and Significance of STAT3 in Adenocarcinoma of Esophagogastric Junction
下载PDF
导出
摘要 目的检测信号转导与转录激活因子3(STAT3)在食管胃交界部腺癌中的表达,探讨其在癌症中的作用。方法采用免疫组织化学的方法,检测2015年6月至2016年12月被河南省肿瘤医院确诊为进展期食管胃交界部腺癌的67例癌症患者,及35例癌旁正常对照组织中STAT3及p-STAT3的表达,用t检验的方法分析两组间STAT3及p-STAT3的表达差异。结果 45例(67.2%)食管胃交界部腺癌高表达STAT3,22例(32.8%)低表达STAT3;34(50.7%)例高表达p-STAT3,33例(49.3%)低表达p-STAT3。且癌组织分化程度越高,STAT3及p-STAT的表达水平则越高。结论 STAT3可能与食管胃交界处腺癌的发生、发展有关,或可成为新的治疗靶点之一。 Objective To detect the expression of signal transducer and activator of transcription 3 ( STAT3 ) in adenocarcinoma of esophagogastric junction (AEJ) and explore its role in AEJ. Methods Immunohistochemical method was used to detect the expression of STAT3 and p-STAT3 in 67 cases of AEJ which were collected from June 2015 to December 2016 and diagnosed by Henan province tumor hospital. At the same time, 35 cases of normal control tissues were also measured. The difference of expression levels of STAT3 and p-STAT3 between the two groups was analyzed by t test. Results 45 cases (67.2%)AEJ had high expression of STAT3 and 22 cases ( 32. 8% ) with low expression. 34 ( 50. 7% ) cases AEJ had high expression of p-STAT3 and 33 (49.3%)had low expression. And the higher differentiation degree of cancer tissue, the higher the expression level of STAT3 and p- STAT3 were observed. Conclusion: STAT3 may be related to the occurrence and development of AEJ, and may be one of the new therapeutic targets.
出处 《标记免疫分析与临床》 CAS 2018年第2期155-157,共3页 Labeled Immunoassays and Clinical Medicine
基金 河南省科技攻关计划项目(162102310041)
关键词 食管胃交界部腺癌 信号转导与转录激活因子3(STAT3) 表达 Adenocarcinoma of Esophagogastric Junction (AEJ) Signal transducer and activator oftranscription 3 (STAT3) Expression
  • 相关文献

参考文献3

二级参考文献18

  • 1Burkhard HA von Rahden,Hubert J Stein,J Rüdiger Siewert.Surgical management of esophagogastric junction tumors[J].World Journal of Gastroenterology,2006,12(41):6608-6613. 被引量:18
  • 2Husemann B.Cardia carcinoma considered as a distinct clinical entity.Br J Surg,1989,76(2):136-139.
  • 3Siewert JR,Holscher AH,Becker K,et al.Cardia cancer:attempt at a therapeuticaiiy relevant classification.Chirurg,1987,58(1):25-32.
  • 4Siewert JR,Stein HJ.Classification of the adenocarcinoma of the esophagogastric junction.Br J Surg,1998,85(11):1457-1459.
  • 5Siewert JR,Feith M,Stein HJ.Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction:relevance of a topographic-anatomic subclassification.J Surg Oncol,2005,90(3):139-146.
  • 6Barboer AP,Rizk NP,Gonen M,et al.Adenocarcinoma of the gastroesophageal junction influence of esophageal resection margin and operative approach on outcome.Ann Surg,2007,246(1):1-8.
  • 7Feith M,Stein HJ,Siewert JR,et al.Adenocarcinoma of the esophagogastric junction:surgical therapy based on 1602 consecutive resected patients.Surg Oncol Clin N Am,2006,15(4):751-764.
  • 8Hulscher JB,Tijssen JG,Obertop H,et al.Transthoracic versus transhiatal resection for carcinoma of the esophagus:a meta-analysis.Ann Thorac Surg,2001,72(1):306-313.
  • 9Stein HJ,Feith M,Siewert JR.Cancer of the esophagogastric junction.Surg Oncol,2000,9(1):35-41.
  • 10Hulscher JB,van Sandick JW,de Boer AG,et al.Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus.N Engl J Med,2002,347(21):1662-1669.

共引文献42

同被引文献29

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部